{
  "id": 198295,
  "name": "KIDNEY CARE PARTNERS",
  "slug": "kidney-care-partners",
  "state": "DC",
  "description": "Health care",
  "totalSpending": 1575000,
  "filings": 26,
  "yearlySpending": [
    {
      "year": 2018,
      "income": 180000
    },
    {
      "year": 2019,
      "income": 180000
    },
    {
      "year": 2020,
      "income": 240000
    },
    {
      "year": 2021,
      "income": 120000
    },
    {
      "year": 2022,
      "income": 240000
    },
    {
      "year": 2023,
      "income": 240000
    },
    {
      "year": 2024,
      "income": 180000
    },
    {
      "year": 2025,
      "income": 195000
    }
  ],
  "firms": [
    "LESTER HEALTH LAW PLLC"
  ],
  "lobbyists": [
    "KATHLEEN LESTER"
  ],
  "issues": [
    "HCR",
    "MMM",
    null
  ],
  "sampleDescriptions": [
    "Affordable Care Act Implementation; Marketplace Stabilization Rules; Charitable Premium Assistance",
    "ESRD Prospective Payment System CY 2018 and CY 2019 and Quality Incentive Program PY 2019-21 and PY 2022; ESRD Dialysis Facility Compare/Five Star; implementation of ESRD PPS for CY 2017; HR 2644 Chronic Kidney Disease Improvement in Research and Treatment Act of 2017; S. 1890 Chronic Kidney Disease Improvement in Research and Treatment Act of 2017",
    "ESRD Prospective Payment System CY 2019 and Quality Incentive Program PY 2019-22; ESRD Dialysis Facility Compare/Five Star; implementation of ESRD PPS for CY 2018; HR 2644 Chronic Kidney Disease Improvement in Research and Treatment Act of 2017; S. 1890 Chronic Kidney Disease Improvement in Research and Treatment Act of 2017",
    "Implementation of ESRD Prospective Payment System (PPS) CY 2020 and Quality Incentive Program (QIP) PY 2020-23 Proposed Rule; ESRD Five Star Program; Proposed ESRD PPS and QIP rules",
    "Affordable Care Act Implementation, including Notice of Benefits and Payment Parameters rules; Marketplace Stabilization Rules;",
    "Affordable Care Act Implementation, including Notice of Benefits and Payment Parameters rules; Marketplace Stabilization Rules; S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019",
    "Implementation of ESRD Prospective Payment System (PPS) CY 2020 and Quality Incentive Program (QIP) PY 2020-23 Proposed Rule; ESRD Five Star Program; Proposed ESRD PPS and QIP rules; S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019;  ESRD Treatment Choices Model proposed rule",
    "Affordable Care Act Implementation, including Notice of Benefits and Payment Parameters rules; Marketplace Stabilization Rules; S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; OPO proposed rule; HRSA organ compensation proposed rule",
    "Implementation of ESRD Prospective Payment System (PPS) CY 2020 and Quality Incentive Program (QIP) PY 2020-23 Proposed Rule; ESRD Five Star Program; Proposed ESRD PPS and QIP rules; S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019;  ESRD Treatment Choices Model proposed rule; ESRD Voluntary physician models",
    "Affordable Care Act Implementation, including Notice of Benefits and Payment Parameters rules; Marketplace Stabilization Rules; S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; OPO proposed rule; HRSA organ compensation proposed rule, CARES Act",
    "Implementation of ESRD Prospective Payment System (PPS) CY 2020 and Quality Incentive Program (QIP) PY 2020-23 Proposed Rule; ESRD Five Star Program; Proposed ESRD PPS and QIP rules; S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019;  ESRD Treatment Choices Model proposed rule; ESRD Voluntary physician models, CARES Act, COVID-19 1135 Waiver policies",
    "Affordable Care Act Implementation, including Notice of Benefits and Payment Parameters rules; Marketplace Stabilization Rules; S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; OPO proposed rule; CARES Act; HHS COVID-19 Interim Final Rules",
    "Affordable Care Act Implementation, including Notice of Benefits and Payment Parameters rules; Marketplace Stabilization Rules; S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; NOTA proposed and final rule; OPO proposed and final rule; CARES Act; HHS COVID-19 Interim Final Rules",
    "ESRD Prospective Payment System CY 2021 and Quality Incentive Program PY 2023-24 Proposed Rule; Implementation of ESRD Prospective Payment System (PPS) CY 2020 and Quality Incentive Program (QIP) PY 2020-23 Proposed Rule; ESRD Five Star Program; S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019;  ESRD Treatment Choices Model proposed rule; ESRD Voluntary physician models, CARES Act, COVID-19 1135 Waiver policies",
    "Affordable Care Act Implementation, including Notice of Benefits and Payment Parameters rules; Marketplace Stabilization Rules; S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; NOTA proposed and final rule; OPO proposed and final rule; CARES Act; HHS COVID-19 Interim Final Rules; H.R.133 - Consolidated Appropriations Act, 2021; vaccine prioritization issues",
    "ESRD Prospective Payment System CY 2021 and Quality Incentive Program PY 2023-24 Proposed Rule; Implementation of ESRD Prospective Payment System (PPS) CY 2020 and Quality Incentive Program (QIP) PY 2020-23 Proposed Rule; ESRD Five Star Program; S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019;  ESRD Treatment Choices Model proposed rule; ESRD Voluntary physician models, CARES Act, COVID-19 1135 Waiver policies; H.R.133 - Consolidated Appropriations Act, 2021; vaccine prioritization issues",
    "ESRD prospective payment system, quality incentive program, ESRD Treatment Choices Model, Medicare Advantage program, COVID-19 relief guidance; S. 1971/H.R. \"Chronic Kidney Disease Improvement in Research and Treatment Act of 2021\"",
    "COVID-19 provider relief fund, organ procurement regulations, living donor compensation regulations",
    "ESRD prospective payment system, quality incentive program, ESRD Treatment Choices Model, Medicare Advantage program, COVID-19 relief guidance; S. 1971/H.R. \"Chronic Kidney Disease Improvement in Research and Treatment Act of 2021\"; HHS transplant ecosystem request for information.",
    "COVID-19 provider relief fund, organ procurement regulations, living donor compensation regulations; HHS transplant ecosystem request for information"
  ],
  "years": [
    2018,
    2019,
    2020,
    2021,
    2022,
    2023,
    2024,
    2025
  ],
  "growthRate": 8,
  "trajectory": "stable",
  "yearsActive": 8,
  "avgAnnualSpending": 196875,
  "peakYear": 2020,
  "lobbyistCount": 1,
  "firmCount": 1,
  "issueCount": 2
}